Hoersholm; September 4th 2015 – Medical Prognosis Institute A/S (MPI) announces that three abstracts have been accepted for presentation on the AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5 – 9 2015, Hynes Convention Center, Boston, Massachusetts.
“I’m very happy that three abstracts have been accepted for this very important scientific cancer meeting which is organized as an international collaboration between the US and European cancer expert scientists working in the pre-clinic and early clinic space. I believe that these presentations on this conference is important for the MPI DRP(TM) technology,” Said Professor Peter Buhl Jensen, M.D., CEO of MPI.
| Abstract Number: A182 | |
| Title: | Targeting the topoisomerase 1 enzyme in cancer cells with acquired resistance to SN-38 |
| Session ID: | Poster Session A |
| Session Title: | Topoisomerase Inhibitors |
| Session Date and Time: | Friday Nov 6, 2015 12:15 PM – 3:15 PM |
| Location: | Exhibit Hall C-D |
| Abstract Number: B71 | |
| Title: | DEN-50R – establishment of a novel and unique cell line based drug screening platform for cancer treatment |
| Session ID: | Poster Session B |
| Session Title: | Drug Screening |
| Session Date and Time: | Saturday Nov 7, 2015 12:30 PM – 3:30 PM |
| Location: | Exhibit Hall C-D |
| Abstract Number: C168 | |
| Title: | A two stage prospective clinical trial with irofulven treatment targeting a selected subgroup of castration- and docetaxel resistant prostate cancer patients |
| Session ID: | Poster Session C |
| Session Title: | Therapeutic Agents: Biological |
| Session Date and Time: | Sunday Nov 8, 2015 12:30 PM – 3:30 PM |
| Location: | Exhibit Hall C-D |
About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
For further information, please contact
CEO Peter Buhl Jensen, Professor, MD, PhD
E-mail: [email protected]
Cell Phone: (+45) 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark
